Who
Terrance McGuire
Director
Company insider
Files Form 4 as: Director, Seer; Director, Invivyd; Director, Tectonic Therapeutic; Director, Cyclerion Therapeutics; Director and 10% owner, Alector; 10% owner, Lyra Therapeutics; Director and 10% owner, Pulmatrix; Director, Ironwood Pharmaceuticals.
In numbers
- Trades disclosed
- 347
- Buys
- 6
- Sells
- 27
- Bought
- $26.3M
- Sold
- $60.0M
- Companies
- 15
- Companies where not an officer
- 15
- First trade
- 9 May 2006
- Last trade
- 28 Jul 2026
- Last filed
- 30 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Jul 2026filed 30 Jul 2026 | SEER SeerLife-science tools | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 28 Jul 2026filed 30 Jul 2026 | SEER Seeroption or derivative · Life-science tools | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 28 Jul 2026filed 30 Jul 2026 | SEER Seeroption or derivative · Life-science tools | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 28 Jul 2026filed 30 Jul 2026 | SEER SeerLife-science tools | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | IVVD Invivydoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | IVVD Invivydoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 9 Dec 2025filed 11 Dec 2025 | SEER Seeroption or derivative · Life-science tools | SEC FORM 4 Code C | —4,088 at $0.00 | filing |
| 9 Dec 2025filed 11 Dec 2025 | SEER SeerLife-science tools | SEC FORM 4 Code C | —4,088 | filing |
| 7 Jul 2025filed 9 Jul 2025 | SEER Seeroption or derivative · Life-science tools | SEC FORM 4 Code A | —30,500 at $0.00 | filing |
| 7 Jul 2025filed 9 Jul 2025 | SEER SeerLife-science tools | SEC FORM 4 Code A | —20,500 at $0.00 | filing |
| 9 Jun 2025filed 11 Jun 2025 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,200 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | IVVD Invivydoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Apr 2025filed 7 Apr 2025 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Sold | $8.6M500,000 at $17.10 | filing |
| 31 Dec 2024filed 31 Dec 2024 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $47K103,474 at $0.45 | filing |
| 30 Dec 2024filed 31 Dec 2024 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $42K86,545 at $0.48 | filing |
| 27 Dec 2024filed 31 Dec 2024 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $44K83,744 at $0.52 | filing |
| 26 Dec 2024filed 26 Dec 2024 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $45K83,817 at $0.54 | filing |
| 24 Dec 2024filed 26 Dec 2024 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $35K68,161 at $0.51 | filing |
| 23 Dec 2024filed 26 Dec 2024 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $34K75,776 at $0.45 | filing |
| 20 Dec 2024filed 26 Dec 2024 | IVVD InvivydBiotechnology | SEC FORM 4 Sold | $50K119,805 at $0.42 | filing |
News
Insider Buying: X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Acquires $11,868.00 in StockXFOR · tickerreport.com · 22 Oct 2026Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026IVVD · manilatimes.net · 21 Oct 2026Invivyd (NASDAQ:IVVD) and Arcus Biosciences (NYSE:RCUS) Critical ContrastIVVD · themarketsdaily.com · 19 Oct 2026Alector (NASDAQ: ALEC) prices shares at a 7.3% premium in stock saleALEC · dailypolitical.com · 18 Oct 2026Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's TherapiesALEC · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Terrance McGuire; 5 articles from the last 14 days about the 6 companies they traded most, at most three about any one of them.